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Abstract 
Numerous studies have reported a reduced risk of rheumatoid arthritis (RA) in 
schizophrenia. The mechanisms are unknown but recent genome-wide association studies 
of schizophrenia have shown strong associations with markers spanning the major 
histocompatibility complex (MHC) region, indicating a possible role for adaptive 
immunity also in schizophrenia. In this population-based cohort study we assess the 
associations between RA and schizophrenia and the extent to which any observed 
associations are specific to RA/schizophrenia. We then extend the assessments per RA 
subtype and to risks in first-degree relatives. The study population included every 
individual identified in the Swedish Population Register born in Sweden between 1932 
and 1989. The risk for RA in schizophrenia was significantly decreased (HR=0.69; 95% 
CI=0.59-0.80), but similar reductions were noted for osteoarthritis (a non-inflammatory 
joint disorder) and ankylosing spondylitis (a non-RA inflammatory disorder). 
Comparable associations were seen in schizoaffective subjects while no significant 
associations were observed in bipolar disorder. Overall, first-degree relatives of 
schizophrenia patients were not at reduced risk of RA, but the risk for seronegative RA 
was significantly decreased in children and siblings of schizophrenia probands (HR=0.13; 
95% CI=0.02-0.95, and HR=0.67; 95% CI=049-0.92, respectively). In conclusion, our 
intra-individual analyses suggest that differential misclassification bias is an important 
factor for the observed inverse association and emphasize the need of optimized care-
provision for non-psychiatric symptoms in schizophrenia patients. Our familial analyses 
indicted the possibility of an inverse co-inheritance of schizophrenia and seronegative 
RA.  
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Introduction 
Rheumatoid arthritis (RA) is an immune-mediated chronic inflammatory joint disease 
caused by a combination of genetic and environmental factors. The overall heritability of 
RA is estimated to be around 50% and the major histocompatibility complex (MHC) 
region is the single most important genetic risk locus.1 In schizophrenia, there is also 
accumulating evidence for a role of immune signaling.2 For example, an increased 
peripheral concentration of IL-1 receptor antagonist (IL-1Ra) has been reported in 
patients with schizophrenia3 and knockout mice lacking IL-1Ra develop spontaneous 
joint inflammation.4 Recent genome-wide association studies (GWAS) of schizophrenia 
have also found strong associations with markers spanning the MHC region,5 indicating a 
possible role for adaptive immunity also in schizophrenia.  
 
Numerous epidemiological studies have described an inverse association between RA 
and schizophrenia.6-9 The association remains poorly understood but has been suggested 
to be due to a shared immune-related aetiology,10 possibly attributed to genetic factors.7,8 
The majority of these studies have assessed the risk of RA in patients with schizophrenia. 
Since the typical age of onset is higher in RA than in schizophrenia, such assessments 
may be biased by under-reporting or under-diagnosis of RA in patients with severe 
mental disorders.7 An alternative approach that would largely circumvent such 
differential misclassification bias, and also reveal potential common genetic 
determinants, would be to assess the risk of RA in first-degree relatives of probands with 
schizophrenia, and vice versa. Furthermore, “RA” is a criteria-based diagnosis that 
contains aetiologically distinct subtypes, e.g., as defined by the presence of serological 
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markers. Recent studies of RA also suggest that seronegative and seropositive RA, the 
latter defined by presence of rheumatoid factor (RF) and/or anti-citrullinated 
peptide/protein antibodies (ACPA), have different aetiologies and genetic architectures.11 
The MHC is most strongly associated with ACPA-positive RA.12-14 Most, but not all, 
ACPA-positive patients are also RF-positive, and it is estimated that 50–80% of all 
individuals with RA have RF, ACPA, or both.15 Hence, a comprehensive assessment of 
the association between RA and schizophrenia needs to take RA subtype into account. 
 
So far, attempts to study familial associations between RA and schizophrenia have not 
provided conclusive results, mainly because of small samples yielding limited statistical 
precision. Of the four existing studies – none of which were primarily designed to assess 
a familial association between schizophrenia and RA – one study, based on interviews 
with mothers of psychotic patients (n=101), found that RA was significantly less 
common in the mothers, but no association with RA in the patients’ first-degree relatives 
overall was observed.16 In a second, larger study based on national registries, parents of 
schizophrenia patients had a higher than expected prevalence of RA,17 although this 
association did not reach statistical significance. In a third study, based on 515 RA 
patients and 769 controls, 23 subjects had a family-history of schizophrenia, and the 
observed relative risk of approximately 2 did not reach significance.18 However, in the 
same study, patients with RA characterized by the presence of ACPA were at increased 
risk of having a first-degree relative with schizophrenia whereas no such association was 
seen in ACPA-negative RA. The fourth and most recent study explored the risk of 
autoimmune diseases, including RA, in individuals with a family history of schizophrenia 
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spectrum disorder using Danish nationwide registers.9 294 out of 9 697 individuals with a 
register-based diagnosis of RA had a parent or sibling with a diagnosis of schizophrenia 
but the risk was not different from that of the general population. 
 
In this study, we aimed to assess the relative risk of RA in patients with schizophrenia 
and in their first-degree relatives (children, siblings, and parents), using a sufficiently 
large study population and - to the extent possible - assess these risks in relation to 
seropositive and seronegative RA (as defined by the 10th revision of the International 
Classification of Diseases (ICD-10)).19 Also in contrast to previous studies, we assessed 
the risk of schizophrenia in first-degree relatives of RA probands. To gauge effects 
primarily related to diagnostic intensity, we also assessed risks of RA in patients with 
schizoaffective and bipolar disorder (BD). We furthermore investigated the risks of non-
inflammatory musculoskeletal diseases (osteoarthritis [OA]) and inflammatory non-RA 
diseases (ankylosing spondylitis [AS]) in patients with these three major psychotic 
disorders and in their first-degree relatives. 
 
Methods 
Data sources used 
All residents in Sweden receive a 10-digit personal identification number, which is 
consistent throughout all national registries, and hence make register linkage possible.20 
The National Patient Register (NPR; held at The National Board of Health and Welfare) 
contains information on inpatient care since 1964. Diagnoses are reported using the 
ICD.19,21,22 Every record has an admission and discharge date, together with the main 
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diagnosis and secondary diagnoses. Since 2001, the NPR registers corresponding data 
from outpatient visits in specialized non-primary care. The nationwide Multi-Generation 
Register (MGR) (Statistics Sweden) holds information on first-degree relatives of 
Swedish residents born from 1932 and onwards who were alive in or after 1961. In 
addition to the NPR and MGR, we also obtained data from the Migration, Cause of 
Death, and Total Population Register at Statistics Sweden. 
 
Source population 
The study population was defined as every individual identified in the Swedish 
population register born in Sweden between January 1932 and December 1989. 
Immigrants were included if less than 18 years old when registered in Sweden or if they 
immigrated as an adult before January 1958. The study was approved by the Ethics 
committee at Karolinska Institutet, Stockholm, Sweden. 
 
Identification of schizophrenia and other psychiatric diagnoses 
The inpatient component of the NPR contains all public psychiatric inpatient admissions 
in Sweden since 1973 (for outpatient care since 2001). Subjects with schizophrenia were 
identified based on at least one visit listing schizophrenia in the inpatient component of 
the NPR (from 1973 through 2009), or the outpatient non-primary component (from 2001 
through 2009). For comparison reasons, we also identified subjects with schizoaffective 
disorders and BD. Identification of subjects with schizoaffective disorder was also based 
on at least one visit in the NPR listing this diagnosis, while a previously validated 
algorithm, based on two or more separate registrations in the NPR, was used to identify 
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BD subjects.23 The diagnostic structure was non-hierarchical, meaning that a subject 
could have more than one diagnosis. All diagnostic codes were retrieved from the NPR 
and the ICD codes used are listed in eTable 1.  
 
Identification of RA and other musculoskeletal diagnoses 
Subjects with RA were identified based on at least one visit in the NPR listing a RA 
diagnosis from 1997 and through 2009. Start of follow-up was in 1997 when ICD-10 was 
introduced in Sweden (previous ICD classifications do not separate seropositive and 
seronegative RA). To assess effects related to the RA diagnosis per se rather than effects 
related to musculoskeletal symptoms or access to (rheumatology) care, we also identified 
all subjects with at least one visit in the NPR listing a diagnosis of OA or AS (eTable 1). 
 
Study design  
We performed cohort analyses using prospectively recorded register-data. In the intra-
individual analyses, we assessed the association between schizophrenia (exposure) and 
risk of RA (outcome). In the familial analyses, we assessed the association between 
having a first-degree relative with schizophrenia (exposure) and risk of RA overall and 
by subtype (outcome). We also performed analyses of the risk of schizophrenia in first-
degree relatives of patients with RA overall and by subtype. For comparison reasons, the 
same analyses were also run for schizoaffective disorder and BD (instead of 
schizophrenia), and for AS and OA (instead of RA). 
 
Statistical analyses 
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We first analyzed intra-individual risks of developing RA overall and by subtype, AS, 
and OA following a diagnosis of schizophrenia, schizoaffective disorder, or BD, 
respectively. We used Cox regression models with attained age as time-scale and all 
analyses were adjusted for sex. All subjects in the study population were followed from 
birth (or January 1st 1997 if born before this date). Exposure was treated as a time-
varying covariate, such that a person was considered as unexposed before the date of the 
first psychiatric diagnosis, and as exposed thereafter. Follow-up ended with first 
diagnosis of the rheumatological outcome under study, death, emigration, or on 
December 31st 2009. Regarding risk of RA overall, we also performed additional 
analyses using the full study period (start of follow-up in 1973). In a sensitivity analysis 
of RA by subtype, we excluded patients with an RA overall diagnosis before start of 
follow-up in 1997. 
 
We then assessed the risk of RA (overall and by subtype), AS, and OA in first-degree 
relatives of patients with the psychotic disorder under study compared to that of first-
degree relatives of non-patients. Conversely, we also assessed the risk of the psychotic 
disorder under study in first-degree relatives of patients with these rheumatological 
disorders. To verify that the study design was able to identify the anticipated disease-
specific familial associations, we performed additional analyses to assess risk of the 
disorder under study in first-degree relatives of individuals with this disorder. We used 
Cox regression with robust sandwich confidence intervals (attained age as time-scale). 
Exposure was time-varying, here meaning that first-degree relatives were considered 
unexposed up until the date of first occurrence of the proband’s first diagnosis, and as 
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exposed thereafter. Follow-up began at birth (or January 1st 1997) and ended with first 
occurrence of the outcome diagnoses, end-of-follow-up (December 31st 2009), death, or 
emigration. All analyses were adjusted for sex.  
 
Results 
We identified 5 981 124 individuals born in Sweden, and 432 559 individuals born 
outside Sweden, between 1932 and 1989. In total, 31 193 unique individuals with a 
diagnosis of schizophrenia were identified in the NPR. Through linkage with the MGR, 
74 260 first-degree relatives of schizophrenia probands were identified (Table 1). 10 676 
individuals with schizoaffective disorder and 34 744 individuals with BD were identified, 
together with 27 112 first-degree relatives of probands with schizoaffective disorder and 
97 528 first-degree relatives of probands with BD. The median age (interquartile range) 
at first entry for schizophrenia patients was 44 years (19), for schizoaffective disorder 
patients 41 years (19), and for BD patients 38 years (20). The attained age of first-degree 
relatives (children, siblings, parents) at start/end of follow-up was similar to the 
corresponding group of first-degree relatives of schizophrenia probands (data not shown).  
 
Risk of RA overall and by subtype in individuals with schizophrenia 
Schizophrenia patients had a significantly reduced risk of receiving a subsequent 
diagnosis of RA overall (HR=0.69; 95% CI= 0.59-0.80), but also for AS (HR=0.62; 95% 
CI=0.45-0.86) as well as OA (HR=0.49; 95% CI=0.45-0.52). When RA was assessed by 
subtype, the lowest point estimate was observed for seronegative RA (seropositive RA: 
HR=0.68; 95% CI=0.57-0.83 vs. seronegative RA: HR=0.49; 95% CI=0.31-0.77). 
 10
Similar associations were seen in individuals with schizoaffective disorder, while in BD 
the risk of later RA, AS, or OA was not different from that of the general population. All 
relative risks are presented in Figure 1. The inverse association between schizophrenia 
and RA displayed no obvious trend by attained age (eTable 2), and the result of a 
sensitivity analysis requiring two diagnoses to be classified as having schizophrenia was 
similar regarding the risk of later RA (HR=0.72; 95% CI=0.61-0.86). Excluding patients 
with a RA diagnosis before start of follow-up in 1997 had no major influence on the 
results (data not shown), and using the full study period from 1973 the relative risk of RA 
overall in schizophrenia patients was similar to the analysis with start of follow-up in 
1997 (HR=0.76; 95% CI=0.66-0.89; eTable 3). Additional analyses stratified by sex, 
birth year, and birth country (categorized as “Sweden”, “Scandinavia excluding Sweden”, 
and “Other”) were also performed but without any substantial impact on the relative risks 
(RA overall: HR=0.70; 95% CI=0.60-0.82, seropositive RA: HR=0.70; 95% CI=0.58-
0.82, and seronegative RA: HR=0.50; 95% CI=0.32-0.79). Sex-stratified relative risks of 
developing RA overall and by subtype can also be found in eTable 4.  
 
Verification of the familial study design; disease-specific familial associations  
Disease-specific familial risks were similar to what has been shown in previous studies. 
11,24 A family history of RA was associated with a tripled risk for RA (HR=3.4; 95% 
CI=3.2-3.6), and a family history of schizophrenia was associated with an eight-fold risk 
of schizophrenia (HR=8.2; 95% CI=7.6-8.8).  
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Risk of RA overall and by subtype in first-degree relatives of individuals with 
schizophrenia 
No significantly increased or decreased risk of receiving a diagnosis of RA overall could 
be detected in children, siblings, or parents of schizophrenia probands (HR=0.83; 95% 
CI=0.58-1.19, HR=1.07; 95% CI=0.96-1.18, and HR=0.97; 95% CI=0.84-1.12, 
respectively). For seropositive RA, we observed a slightly increased risk in siblings of 
schizophrenia probands (HR=1.16; 95% CI=1.03-1.31), while the risk in children 
(HR=1.00; 95% CI=0.67-1.51) and parents (HR=0.91; 95% CI=0.76-1.09) were 
comparable with that of the general population. For seronegative RA, we noted decreased 
risks in siblings of schizophrenia probands (HR=0.67; 95% CI=0.49-0.92) and in children 
(HR=0.13; 95% CI=0.02-0.95), while the risk in parents did not differ significantly from 
that of the general population (HR=0.98; 95% CI=0.70-1.38). Apart from a small yet 
statistically significant reduction in risk of OA in siblings and parents of patients with 
schizophrenia (HR=0.93; 95% CI=0.89-0.98, and HR=0.88; 95% CI=0.83-0.93, 
respectively), no inverse associations with schizophrenia were noted for OA or AS. All 
relative risks are presented in Figure 2. For schizoaffective disorder or BD, no 
associations were observed with relatives’ risk of RA, neither for RA overall nor per RA 
subtype (eFigure 1A and 1B). We also performed the same analyses only counting 
exposure from 1st January 1997 and onwards, i.e., probands diagnoses before this date 
were not taken into account regarding exposure of the first-degree relatives, with similar 
results (data not shown). 
  
Risk of schizophrenia in first-degree relatives of individuals with RA by subtype 
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Among first-degree relatives of RA probands, all point estimates for schizophrenia were 
below unity. The decreased risk, however, only reached statistical significance in children 
of probands with RA overall (HR=0.80; 95% CI=0.66-0.98). In children of probands with 
seronegative RA, the decreased risk also nearly reached significance (HR=0.54; 95% 
CI=0.30-1.00), Figure 3. For schizoaffective disorder and BD, we only observed a 
significantly increased risk of BD in children of patients with RA overall (HR=1.19; 95% 
CI=1.03-1.37) and an increased risk of schizoaffective disorder in children of patients 
with seronegative RA (HR=1.79; 95% CI=1.04-3.09), while all other risks were 
comparable with that of the general population (eFigure 2A and 2B).  
 
Discussion 
In line with previous reports, we found a significantly decreased risk for RA in subjects 
with a history of schizophrenia. The risks for OA, a non-inflammatory joint disorder, and 
for AS, a non-RA inflammatory disorder, were however similarly decreased, suggesting 
that a substantial part of the observed inverse association between RA and schizophrenia 
may be due to other factors than disease-specific biology. This finding is consistent with 
the results from a prior study reporting a comparable incidence of degenerative 
musculoskeletal disorders and RA in schizophrenia patients.7 Further, we found no 
associations between BD and RA despite a previous study’s report of a shared polygenic 
component of schizophrenia and BD of 68%.25 In light of the more severe loss of 
function in schizophrenia and schizoaffective disorder patients in comparison to BD 
patients,26 this is compatible with differential misclassification bias in the observed 
inverse association between schizophrenia and RA. Interestingly, patients with 
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schizophrenia or related psychosis, have been reported to be at increased risk of other 
autoimmune diseases.9 Hence, if under-reporting or under-diagnosis of RA explains most 
of the inverse association, such differential misclassification bias is most certainly 
sensitive to both type and severity of symptoms. Of clinical importance, these data 
however emphasize the need of assessing and being aware of non-psychiatric symptoms 
in schizophrenia patients. 
 
In the analyses of first-degree relatives of schizophrenia probands, we observed no 
significant associations with RA overall. However, analyzing RA risk by subtype, we 
observed a significantly decreased risk for seronegative RA in children (HR=0.13) and 
siblings (HR=0.67) of schizophrenia probands. Correspondingly, the lowest point 
estimate for schizophrenia was observed in relatives of seronegative RA patients 
(HR=0.54), and the lowest point estimate among schizophrenia patients was also 
observed for seronegative RA (HR=0.49). This was unexpected, as the strongest link with 
MHC has been found for seropositive RA. On the other hand, since seronegative RA is 
considerably less common than seropositive RA, and may in itself be a heterogeneous 
entity, less is known about the aetiology and link to MHC in this RA subset. In BD we 
observed no significantly decreased risk for RA overall, or per subgroup. Molecular 
genetics studies also suggest a greater MHC involvement in schizophrenia compared with 
BD.27 The strongest single nucleotide polymorphism (SNP) association with 
schizophrenia is also located in the extended MHC,5 but the complexity of the region, 
including strong linkage disequilibrium (LD) and a high gene density, has complicated 
efforts to identify causal variations. The classical MHC I haplotype HLA-B*08 has been 
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associated with a decreased risk of schizophrenia.27-29 This motif is reported to 
predispose for RA,30 although hitherto only shown in ACPA-positive RA patients. Both 
MHC class II and I are also involved in synaptic plasticity,31.32 and a direct role for these 
molecules in the pathophysiology of schizophrenia is therefore possible. Importantly, the 
schizophrenia locus is located in a region with high LD and extends over several Mb.5 
‘Tagging’ could hence explain associations between classical motifs and schizophrenia. 
Our epidemiological data also indicate a decreased risk for seronegative RA but not for 
seropositive RA (as defined by ICD-10 codes). Motifs foremost associated with ACPA, 
such as the shared epitopes (SE) alleles of HLA-DRB1,1,30 are therefore unlikely to 
explain the familial associations as the vast majority of ACPA-positive RA patients have 
seropositive RA.  
 
The strengths of our data include the national coverage and the fact that this is the largest 
study of intra-individual and inter-familial associations between schizophrenia and RA. 
The size of our study population in combination with the number of events during follow-
up and the duration of follow-up provided sufficient power to detect even moderate 
differences in risks overall and stratified RA subtype. The use of outpatient data, in 
combination with the hospital discharge register, also diminished the risk of bias related 
to hospitalization rather than the studied disease per se.  
 
A limitation of this study is the use of diagnostic information that depends on data 
provided from national registries. Nevertheless, Swedish register discharge diagnoses of 
schizophrenia have shown a high concordance with diagnoses based on semi-structured 
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interviews.33 Similarly, register-based RA diagnoses have a high diagnostic accuracy and 
correspond to a typical RA prevalence.34 Another drawback of the population-based 
approach is the limited data regarding potential confounders. For example, smoking is 
more common in schizophrenia patients than in their first-degree relatives,35 and the risk 
of developing ACPA-positive RA is associated with a gene-environment interaction 
between smoking and the HLA-DRB1 SE alleles.36 Hence, it is possible that the estimated 
relative risk for seropositive RA in schizophrenia patients (but perhaps not in their first-
degree relatives) was inflated by uncontrolled confounding from smoking. Of note, we 
also observed a significantly increased risk of seropositive RA in schizophrenia siblings. 
However, confounding by smoking could hardly explain the decreased risks for 
seronegative RA in schizophrenia patients and their first-degree relatives. Less is known 
about other environmental triggers for RA, and few other robust gene-environment 
interactions have been reported.1,15 Since the heritability of RA is estimated to be around 
50%, leaving the remaining part to environment and interactions, further uncontrolled 
confounding cannot be excluded. Finally, stratification by ACPA serostatus, in 
combination with RF status (i.e., ICD-10), would have further improved the specificity of 
the heterogeneous RA phenotype.  
 
In conclusion, our analyses suggest that under-reporting, or under-diagnosis, is an 
important factor for the inverse intra-individual association of schizophrenia and RA. 
However, an unexpected inverse association between seronegative RA and schizophrenia 
due to genetic causation cannot be ruled out. Taken together, further molecular genetic 
studies of the association between RA and schizophrenia should include stratification by 
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RA subtype and focus on the unique genetic cause of schizophrenia rather than the 
common genetic cause of schizophrenia and BD.  
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Tables 
 
Table 1. Background characteristics for schizophrenia patients and their relatives. All subjects were identified in a Swedish nationwide 
population-based cohort with earliest start of follow-up in 1997. 
 
Index patients with 
schizophrenia 
Children of patients with 
schizophrenia 
Siblings of patients with 
schizophrenia 
Parents of patients with 
schizophrenia 
Number 31193 13948 44675 15637 
Males/females, % 59/41 52/48 51/49 42/58 
Year of birth, median (IQR)1 1955 (20)1 1973 (15) 1954 (18) 1941 (11)1
Calendar year of first entry, median (IQR) 1997 (5) 1997 (4) 1997 (5) 1998 (8) 
Age at first entry, median (IQR) 44 (19) 26 (15) / 35 (15)2 44 (18) / 54 (18)2 58 (10) / 67 (11)2
Person-time of follow-up evaluation 
(person-years) 
290227 127824 415513 126447 
1Schizophrenia patients without information regarding one or both parents were also included. This was more common for individuals born early in the study period. 
Median paternal/maternal age can hence not be correctly estimated from this data as parents of these individuals do not contribute to median year of birth among parents. 
2Attained age at start/stop follow-up. 
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Figure legends 
 
Figure 1. Relative risks of developing rheumatoid arthritis (RA), overall and by subtype, for 
patients with schizophrenia. For comparison reasons, relative risks of receiving a subsequent 
diagnosis of ankylosing spondylitis (AS) and osteoarthritis (OA) are also shown. All data are 
from a Swedish nationwide population-based cohort with earliest start of follow-up in 1997. 
*Events among exposed/unexposed.  
 
Figure 2. Relative risks of developing rheumatoid arthritis (RA), overall and by subtype, for 
first-degree relatives of probands with schizophrenia. For comparison reasons, relative risks of 
receiving a subsequent diagnosis of ankylosing spondylitis (AS) and osteoarthritis (OA) are also 
shown. All data are from a Swedish nationwide population-based cohort with earliest start of 
follow-up in 1997. *Events among exposed/unexposed.  
  
Figure 3. Relative risks of developing schizophrenia for first-degree relatives of probands with 
rheumatoid arthritis (RA) overall and by subtype.  All data are from a Swedish nationwide 
population-based cohort with earliest start of follow-up in 1997. *Events among 
exposed/unexposed.  
 
 
